• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    8/15/23 5:32:37 PM ET
    $AGLE
    $ALZN
    $CING
    $ELOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGLE alert in real time by email

    Gainers

    • Novo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 23.5% to $0.14 during Tuesday's after-market session. This security traded at a volume of 29.7 million shares come close, making up 590.5% of its average volume over the last 100 days. The company's market cap stands at $21.2 million.
    • Nexalin Technology (NASDAQ:NXL) stock increased by 17.82% to $0.72. The market value of their outstanding shares is at $5.2 million. As per the news, the Q2 earnings report came out 3 days ago.
    • T2 Biosystems (NASDAQ:TTOO) shares moved upwards by 14.7% to $0.68. Today's trading volume for this security ended up closing at 38.1 million shares, which is 43.5 percent of its average volume over the last 100 days. The company's market cap stands at $226.1 million.
    • MSP Recovery (NASDAQ:LIFW) shares moved upwards by 14.19% to $0.14. This security traded at a volume of 921.3K shares come close, making up 323.6% of its average volume over the last 100 days. The company's market cap stands at $45.3 million.
    • Alzamend Neuro (NASDAQ:ALZN) stock increased by 7.73% to $0.33. The market value of their outstanding shares is at $31.8 million.
    • Tenon Medical (NASDAQ:TNON) shares moved upwards by 7.61% to $0.23. The market value of their outstanding shares is at $4.8 million.

    Losers

    • Impel Pharmaceuticals (NASDAQ:IMPL) stock decreased by 33.3% to $0.72 during Tuesday's after-market session. The company's market cap stands at $17.0 million.
    • Tempest Therapeutics (NASDAQ:TPST) shares fell 7.52% to $0.62. The market value of their outstanding shares is at $7.1 million. As per the press release, Q2 earnings came out 3 days ago.
    • Eloxx Pharmaceuticals (NASDAQ:ELOX) stock decreased by 6.54% to $5.13. The company's market cap stands at $11.1 million.
    • Aeglea BioTherapeutics (NASDAQ:AGLE) shares decreased by 5.99% to $0.44. The company's market cap stands at $42.8 million. As per the news, the Q2 earnings report came out 2 days ago.
    • Kezar Life Sciences (NASDAQ:KZR) stock declined by 5.85% to $1.45. The market value of their outstanding shares is at $105.4 million. As per the press release, Q2 earnings came out 3 days ago.
    • Cingulate (NASDAQ:CING) stock decreased by 5.67% to $0.58. This security traded at a volume of 108.6K shares come close, making up 26.2% of its average volume over the last 100 days. The company's market cap stands at $8.0 million. As per the news, the Q2 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGLE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGLE
    $ALZN
    $CING
    $ELOX

    CompanyDatePrice TargetRatingAnalyst
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    Kezar Life Sciences Inc.
    $KZR
    10/17/2025$7.00Buy → Hold
    Jefferies
    Kezar Life Sciences Inc.
    $KZR
    10/17/2025Outperform → Mkt Perform
    William Blair
    Tempest Therapeutics Inc.
    $TPST
    4/10/2025Sector Outperform → Sector Perform
    Scotiabank
    Tempest Therapeutics Inc.
    $TPST
    4/10/2025Buy → Neutral
    H.C. Wainwright
    Cingulate Inc.
    $CING
    1/10/2025$12.00Buy
    ROTH MKM
    Tempest Therapeutics Inc.
    $TPST
    3/14/2024$13.00Sector Outperform
    Scotiabank
    Tempest Therapeutics Inc.
    $TPST
    2/8/2024$15.00Buy
    Jefferies
    More analyst ratings

    $AGLE
    $ALZN
    $CING
    $ELOX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:19 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Werth Peter J. bought $98,053 worth of shares (19,455 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ALZN
    $CING
    $ELOX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ALZN
    $CING
    $ELOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tempest Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Tempest Therapeutics from Neutral to Buy and set a new price target of $11.00

    1/22/26 8:24:05 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences downgraded by Jefferies with a new price target

    Jefferies downgraded Kezar Life Sciences from Buy to Hold and set a new price target of $7.00

    10/17/25 8:25:43 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences downgraded by William Blair

    William Blair downgraded Kezar Life Sciences from Outperform to Mkt Perform

    10/17/25 8:25:32 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ALZN
    $CING
    $ELOX
    SEC Filings

    View All

    SEC Form SC14D9C filed by Kezar Life Sciences Inc.

    SC14D9C - Kezar Life Sciences, Inc. (0001645666) (Subject)

    4/3/26 4:58:58 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

    8-K - Kezar Life Sciences, Inc. (0001645666) (Filer)

    4/3/26 4:49:16 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Tempest Therapeutics Inc.

    D - Tempest Therapeutics, Inc. (0001544227) (Filer)

    4/3/26 2:28:03 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ALZN
    $CING
    $ELOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempest Reports Year End 2025 Financial Results and Provides Business Update

    Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the year ended December 31, 2025, and provided a corporate update. "2025 was a transformative year for Tempest as we stre

    3/30/26 9:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has entered into a definitive merger agreement (the "Merger Agreement") to acquire Kezar Life Sciences, Inc. (NASDAQ:KZR), a biotechnology company focusing on small-molecule therapeutics to treat unmet needs in autoimmunity and cancer, for $6.955 in cash per share of Kezar common stock, plus one non-transferable contingent value right ("CVR"), which represents the right to receive: (i) potential payments relating to the ongoing clinical development or disposition of zetomipzomib; (ii) certain proce

    3/30/26 8:00:00 AM ET
    $AUPH
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

    Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonateSuperior Brain Penetration: AL001 showed numerically higher lithium concentrations in all measured brain regions, including whole brainFaster Brain Uptake: AL001 reached peak brain concentration in 6.7 hours vs. 8.4 hours for standard lithium carbonateATLANTA, March 26, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-trauma

    3/26/26 8:00:00 AM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ALZN
    $CING
    $ELOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Trojanowski Justin

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    4/2/26 5:00:36 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Maestas Nicholas

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    4/2/26 5:00:35 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Angel Matthew

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    3/25/26 5:32:36 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ALZN
    $CING
    $ELOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by T2 Biosystems Inc.

    SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

    11/14/24 3:38:45 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    $AGLE
    $ALZN
    $CING
    $ELOX
    Leadership Updates

    Live Leadership Updates

    View All

    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

    HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

    11/13/25 9:15:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights. Recent Highlights (Post-Q3) FDA Accepts NDA for CTx-1301; PDUFA Date Set for May 31, 2026In October of 2025, the U.S. Food and Drug Administration (FDA) accepted Cingulate's New Drug Application

    11/13/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

    Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate's transition toward commercialization pending FDA approval Company also strengthens its cash position by completing a $6 million financing KANSAS CITY, Kan., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced the appointment of Bryan Downey as Chief Commercial Officer, following the U.S. Food and Drug Administration's (FDA) acceptance of Cingulate's New Drug Application (ND

    11/10/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ALZN
    $CING
    $ELOX
    Financials

    Live finance-specific insights

    View All

    Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

    BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the "Record Date") for the distribution of warrants to purchase Tempest common stock ("Warrants") as a dividend (the "Warrant Dividends"), as contemplated by Tempest's previously announced Asset Purchase Agreement (the "Asset Purchase Agreement") with Erigen LLC and Factor Bioscience Inc. The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of c

    1/20/26 5:20:02 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

    Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2025, and provided recent highlights. Recent Highlights: On July 31, 2025, Cingulate submitted its NDA to the FDA for CTx-1301, a novel, extended-release tablet formulation

    8/19/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

    Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended March 31, 2025, and provided a clinical and business update. Highlights include the completion of the Pre-NDA meeting for CTx-1301 and grant received to accelerate

    5/8/25 4:30:00 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care